Skip to main content

Articles

Page 23 of 25

  1. Modulation of the gamma-secretase enzyme, which reduces the production of the amyloidogenic Aβ42 peptide while sparing the production of other Aβ species, is a promising therapeutic approach for the treatment of ...

    Authors: Robyn M Loureiro, Jo Ann Dumin, Timothy D McKee, Wesley F Austin, Nathan O Fuller, Jed L Hubbs, Ruichao Shen, Jeff Jonker, Jeff Ives, Brian S Bronk and Barbara Tate
    Citation: Alzheimer's Research & Therapy 2013 5:19
  2. Curcuminoids may improve pathological conditions associated with Alzheimer's disease. However, their therapeutic potential is limited by their exceedingly low bioavailability after oral administration. A metho...

    Authors: Wolfgang W Quitschke, Nicole Steinhauff and Jean Rooney
    Citation: Alzheimer's Research & Therapy 2013 5:16
  3. Heterogeneity in risk of conversion to Alzheimer's disease (AD) among individualswith mild cognitive impairment (MCI) is well known. Novel statistical methods thatare based on partially ordered set (poset) mod...

    Authors: Curtis Tatsuoka, Huiyun Tseng, Judith Jaeger, Ferenc Varadi, Mark A Smith, Tomoko Yamada, Kathleen A Smyth and Alan J Lerner
    Citation: Alzheimer's Research & Therapy 2013 5:14
  4. The US Food and Drug Administration approved a 23 mg daily dose of donepezil for treatment of moderate to severe Alzheimer's disease (AD) based on outcomes from a large trial comparing the 23 mg/day dose with ...

    Authors: Steven Ferris, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Marwan Sabbagh, Liang Liu, Joan Mackell and Randi Fain
    Citation: Alzheimer's Research & Therapy 2013 5:12
  5. The clinical, neuropsychiatric and neuroimaging features of patients who carry the important new C9ORF72 mutation are discussed in this special series of Alzheimer's Research & Therapy. First reported in November...

    Authors: Bruce L Miller
    Citation: Alzheimer's Research & Therapy 2013 5:7
  6. The Alzheimer's Drug Discovery Foundation's 13th International Conference on Alzheimer's Drug Discovery was held on 10-11 September 2012 in Jersey City, NJ, USA. This meeting report provides an overview of Alz...

    Authors: Rachel F Lane, Penny A Dacks, Diana W Shineman and Howard M Fillit
    Citation: Alzheimer's Research & Therapy 2013 5:5
  7. The characteristics of dementia relating to excessive alcohol use have received increased research interest in recent times. In this paper, the neuropathology, nosology, epidemiology, clinical features, and ne...

    Authors: Nicole J Ridley, Brian Draper and Adrienne Withall
    Citation: Alzheimer's Research & Therapy 2013 5:3
  8. Memantine and cholinesterase inhibitors potentially offer additional benefits in Alzheimer's disease (AD) when used together. This study assessed the efficacy and safety of combination treatment with memantine...

    Authors: Alireza Atri, José L Molinuevo, Ole Lemming, Yvonne Wirth, Irena Pulte and David Wilkinson
    Citation: Alzheimer's Research & Therapy 2013 5:6
  9. 18F-florbetaben and positron emission tomography were used to examine the relationships between β-amyloid (Aβ) deposition, cognition, hippocampal volume, and white matter hyperintensities in mild cognitive impai....

    Authors: Kevin Ong, Victor L Villemagne, Alex Bahar-Fuchs, Fiona Lamb, Gaël Chételat, Parnesh Raniga, Rachel S Mulligan, Olivier Salvado, Barbara Putz, Katrin Roth, Colin L Masters, Cornelia B Reininger and Christopher C Rowe
    Citation: Alzheimer's Research & Therapy 2013 5:4
  10. With increasing knowledge of clinical in vivo biomarkers and the pathological intricacies of Alzheimer's disease (AD), nosology is evolving. Harmonized consensus criteria that emphasize prototypic illness continu...

    Authors: Benjamin Lam, Mario Masellis, Morris Freedman, Donald T Stuss and Sandra E Black
    Citation: Alzheimer's Research & Therapy 2013 5:1
  11. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a circulating enzyme with pro-inflammatory and oxidative activities associated with cardiovascular disease and ischemic stroke. While high plasma Lp-PLA2 activ...

    Authors: Julie E Davidson, Andrew Lockhart, Leslie Amos, Heide A Stirnadel-Farrant, Vincent Mooser, Marc Sollberger, Axel Regeniter, Andreas U Monsch and Michael C Irizarry
    Citation: Alzheimer's Research & Therapy 2012 4:51
  12. Frontotemporal dementia (FTD) is a common dementia syndrome in patients under the age of 65 years with many features overlapping with amyotrophic lateral sclerosis (ALS). The link between FTD and ALS has been ...

    Authors: Sharon J Sha and Adam Boxer
    Citation: Alzheimer's Research & Therapy 2012 4:46
  13. Hexanucleotide expansion intronic to chromosome 9 open reading frame 72 (C9ORF72) has recently been identified as the most common genetic cause of both familial and sporadic amyotrophic lateral sclerosis and of f...

    Authors: Jennifer S Yokoyama and Howard J Rosen
    Citation: Alzheimer's Research & Therapy 2012 4:45
  14. Curcumin is a polyphenolic compound derived from the plant Curcuma Long Lin that has been demonstrated to have antioxidant and anti-inflammatory effects as well as effects on reducing beta-amyloid aggregation. It...

    Authors: John M Ringman, Sally A Frautschy, Edmond Teng, Aynun N Begum, Jenny Bardens, Maryam Beigi, Karen H Gylys, Vladimir Badmaev, Dennis D Heath, Liana G Apostolova, Verna Porter, Zeba Vanek, Gad A Marshall, Gerhard Hellemann, Catherine Sugar, Donna L Masterman…
    Citation: Alzheimer's Research & Therapy 2012 4:43
  15. Therapeutic products that depend on the use of an in vitro diagnostic biomarker test to confirm their effectiveness are increasingly being developed. Use of biomarkers is particularly meaningful in the context of...

    Authors: Hugo Vanderstichele, Erik Stoops, Eugeen Vanmechelen and Andreas Jeromin
    Citation: Alzheimer's Research & Therapy 2012 4:39
  16. Earlier reports of chromosome 9p-linked frontotemporal dementia (FTD) with amyotrophic lateral sclerosis (ALS) kindreds observed psychosis as a prominent feature in some patients. Since the discovery of chromo...

    Authors: Leonel T Takada and Sharon J Sha
    Citation: Alzheimer's Research & Therapy 2012 4:38
  17. Mutation in chromosome 9 open reading frame 72 (C9orf72) is a major genetic cause of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), referred to as C9FTD/ALS. The function of the protein is...

    Authors: Tibor Hortobágyi
    Citation: Alzheimer's Research & Therapy 2012 4:37
  18. Frontotemporal dementia (FTD) is a common cause of early-onset dementia with a significant genetic component, as underlined by the recent identification of repeat expansions in the gene C9ORF72 as a major cause o...

    Authors: Colin J Mahoney, Laura E Downey, Gerard R Ridgway, Jon Beck, Shona Clegg, Melanie Blair, Sarah Finnegan, Kelvin K Leung, Tom Yeatman, Hannah Golden, Simon Mead, Jonathan D Rohrer, Nick C Fox and Jason D Warren
    Citation: Alzheimer's Research & Therapy 2012 4:41
  19. Dementia is starting to attract attention following decades of comparative neglect relative to other disease areas. England has been at the forefront of this sea change as one of the first countries in the wor...

    Authors: Zeinab Abdi and Alistair Burns
    Citation: Alzheimer's Research & Therapy 2012 4:36
  20. Some familial Alzheimer's disease (AD) cases are caused by rare and highly-penetrant mutations in APP, PSEN1, and PSEN2. Mutations in GRN and MAPT, two genes associated with frontotemporal dementia (FTD), have be...

    Authors: Sheng Chih Jin, Pau Pastor, Breanna Cooper, Sebastian Cervantes, Bruno A Benitez, Cristina Razquin, Alison Goate and Carlos Cruchaga
    Citation: Alzheimer's Research & Therapy 2012 4:34
  21. Chromosome 9 open reading frame 72 (C9orf72) is an evolutionarily conserved protein with unknown function, expressed at high levels in the brain. An expanded hexanucleotide GGGGCC repeat located in the first i...

    Authors: Jun-ichi Satoh, Hiroko Tabunoki, Tsuyoshi Ishida, Yuko Saito and Kunimasa Arima
    Citation: Alzheimer's Research & Therapy 2012 4:33
  22. An expanded hexanucleotide repeat in the C9ORF72 gene has recently been identified as an important cause of frontotemporal dementia and motor neuron disease; however, the phenotypic spectrum of this entity and it...

    Authors: Laura E Downey, Colin J Mahoney, Martin N Rossor, Sebastian J Crutch and Jason D Warren
    Citation: Alzheimer's Research & Therapy 2012 4:42
  23. Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the deposition of β-amyloid (Aβ) in the brain, which produces progressive neuronal loss and dementia. We recently demonstrated that the...

    Authors: Pedro J Chacón and Alfredo Rodríguez-Tébar
    Citation: Alzheimer's Research & Therapy 2012 4:31
  24. Numerous kindreds with familial frontotemporal dementia or amyotrophic lateral sclerosis or both have been linked to chromosome 9 (c9FTD/ALS), and an expansion of the GGGGCC hexanucleotide repeat in the non-co...

    Authors: Bradley F Boeve and Neill R Graff-Radford
    Citation: Alzheimer's Research & Therapy 2012 4:29
  25. Behavioural and psychological symptoms of dementia (BPS) include depressive symptoms, anxiety, apathy, sleep problems, irritability, psychosis, wandering, elation and agitation, and are common in the non-demen...

    Authors: Rianne M van der Linde, Blossom CM Stephan, George M Savva, Tom Dening and Carol Brayne
    Citation: Alzheimer's Research & Therapy 2012 4:28
  26. Clinical research is best done when aligned with clinical care - that is, when the patient can be identified, recruited and, in many instances, researched in parallel with the delivery of clinical service. How...

    Authors: Piers Kotting, Kris Beicher, Ian G McKeith and Martin N Rossor
    Citation: Alzheimer's Research & Therapy 2012 4:23
  27. Alzheimer's disease is an age-associated, irreversible, progressive neurodegenerative disease that is characterized by severe memory loss, unusual behavior, personality changes, and a decline in cognitive func...

    Authors: Rammohan V Rao, Olivier Descamps, Varghese John and Dale E Bredesen
    Citation: Alzheimer's Research & Therapy 2012 4:22
  28. The current pathological confirmation of the diagnosis of Alzheimer's disease (AD) is still based on postmortem identification of parenchymal amyloid beta (Aβ) plaques, intra-neuronal neurofibrillary tangles, ...

    Authors: Amanda Hanna, Kayleigh Iremonger, Pritam Das, Dennis Dickson, Todd Golde and Christopher Janus
    Citation: Alzheimer's Research & Therapy 2012 4:21
  29. Neuropathological studies have revealed the presence of a broad variety of inflammation-related proteins (complement factors, acute-phase proteins, pro-inflammatory cytokines) in Alzheimer's disease (AD) brain...

    Authors: Piet Eikelenboom, Jeroen JM Hoozemans, Rob Veerhuis, Eric van Exel, Annemieke JM Rozemuller and Willem A van Gool
    Citation: Alzheimer's Research & Therapy 2012 4:15